
Cobalis Corp.: Specialty pharma firm developing treatments for atopic diseases and allergy prevention.
Founded with a mission to develop innovative treatments for atopic diseases, Cobalis Corp. is a specialty pharmaceutical company focused on preventing and treating conditions such as allergies, migraine headaches, atopic asthma, and dermatitis. Their flagship product, PreHistin, is an allergy prevention medication currently in Phase III clinical development. Cobalis aims to secure FDA approval to market PreHistin as an over-the-counter medication in the United States.
Cobalis has garnered attention from notable investors and industry experts who recognize the potential impact of their groundbreaking work. The company's key achievements include advancing PreHistin through critical phases of clinical trials, positioning it as a promising solution for allergy sufferers. By focusing on unmet medical needs in the atopic disease market, Cobalis is poised to make significant contributions to improving patient outcomes and quality of life.

Corbus Pharmaceuticals Holdings
corbuspharma.com

ClostraBio
clostrabio.com

Corsair Pharma
corsairpharma.com

Accuitis
accuitis.com

Stocosil

Allermi

Halia Therapeutics

HI-Bio
hibio.com

Attralus
attralus.com

Collegium Pharmaceutical

Cambrian BioPharma
cambrianbio.com

Epalex
epalex.com

Argentis Pharmaceuticals
argentisrx.com

Allergenis
allergenis.com

Microdermis
Companies similar to Cobalis include Corbus Pharmaceuticals Holdings, ClostraBio, Corsair Pharma and Accuitis.
Cobalis was founded in 1997.
Cobalis' headquarters is located in Irvine, CA, US.
Cobalis' most recent funding round was for $3.9M (USD) in February 2007.
As of Feb 22, 2007, Cobalis has raised a total of $6.3M (USD).
Cobalis has 6 employees as of Feb 5, 2024.